Brief: Arcutis Biotherapeutics Says New Data Shows ZORYVE Cream 0.3% Provided Measurable Improvement Of Plaque Psoriasis

Arcutis Biotherapeutics

20/10/2023 13:22

Oct 20 (Reuters) - Arcutis Biotherapeutics Inc  ARQT.O :
    * ARCUTIS BIOTHERAPEUTICS : DATA SHOWS ZORYVE® CREAM 0.3%
PROVIDED
MEASURABLE IMPROVEMENT OF PLAQUE PSORIASIS IN NEARLY ALL
INDIVIDUALS IN DERMIS TRIALS
    * ARCUTIS BIOTHERAPEUTICS INC: OVER 85% ACHIEVED MEASURABLE
IMPROVEMENT BY WEEK 2 ( EARLIEST TIMEPOINT MEASURED) IN STUDY
    * ARCUTIS : SEPARATELY REPORTED NEW DATA CONFIRMS ZORYVE IS
WELL
TOLERATED ACCORDING TO BOTH INVESTIGATOR AND PATIENT LOCAL
TOLERABILITY ASSESSMENTS

Source text for Eikon:  ID:nGNX1wWFjp 
Further company coverage:  ARQT.O 

 ((Reuters.Briefs@thomsonreuters.com;))